Dr. Julio M. Pow-Sang, MD

Dr. Pow-Sang practices at H Lee Moffitt Cancer Center & Research Institute I - HOPD in Tampa, Florida.

Dr. Pow-Sang's NPI, 1427078229, was assigned on July 21, 2006. Dr. Pow-Sang graduated from Universidad Autonoma de Guadalajara in 1978. Dr. Pow-Sang holds Florida license ME41724.

Dr. Pow-Sang's primary practice is H Lee Moffitt Cancer Center & Research Institute I - HOPD, at 10901 McKinley Dr, Tampa, FL 33612.

Dr. Pow-Sang's primary practice is H Lee Moffitt Cancer Center & Research Institute I - HOPD in Tampa, Florida. Dr. Pow-Sang is also affiliated with Moffitt Cancer Hospital. The medical group on file is Moffitt Cancer Center. Dmand AI also links Dr. Pow-Sang to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Pow-Sang practices, 3 sites in all. Vendor and product names are available with a free account.

Urology is Dr. Pow-Sang's primary specialty in the NPI Registry, under taxonomy code 208800000X. Dr. Pow-Sang is board certified in urology by the American Board of Urology. Dr. Pow-Sang is licensed in Florida.

Dmand AI lists enlarged prostate, prostate cancer, prostate surgery, urinary endoscopy and urine flow blockage among the conditions Dr. Pow-Sang treats.

CMS data shows 750 Medicare services from Dr. Pow-Sang across 12 procedure codes in 2024, for 371 Medicare patients. Medicare paid $69,463 for them.

CMS counts 371 Medicare patients who saw Dr. Pow-Sang in 2024. The largest group is 65 to 74, with 233 patients. 75% of them have cancer, and 75% have high blood pressure. Their average risk score is 0.96, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Pow-Sang's median patient age at 71, with 0% women.

In 2024, Dr. Pow-Sang wrote 151 Medicare Part D claims for 62 patients. 100% of them were for generic drugs. CMS names the drug for 119 of them, across 3 drugs with 11 or more claims each, at $1,150 in total drug cost. In 2023, CMS named 114 claims across 3 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Pow-Sang for performance year 2024, reported as part of a group. Dr. Pow-Sang accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Pow-Sang as offering telehealth. CMS counts 14 procedures of prostate resection by Dr. Pow-Sang, more than 69% of the clinicians it reports for that procedure.

Dmand AI links 188 papers to Dr. Pow-Sang, published from 2006 to 2025. 2020 was the busiest year, with 10. The most frequent topics are Prostatic Neoplasms, Urinary Bladder Neoplasms and Prostatectomy. Dr. Pow-Sang has published most often in Cancer Control. Dr. Pow-Sang's most frequent co-authors are Philippe E. Spiess, MD, Wade J. Sexton, MD and Michael A. Poch, MD.

Dmand AI links Dr. Pow-Sang to 10 clinical trials, 3 of them phase 1 studies. 3 are still active or recruiting. Conditions studied include Prostatic Neoplasms, Prostatic Diseases and Carcinoma, Transitional Cell. H. Lee Moffitt Cancer Center and Research Institute sponsors the most, 10.

CMS Open Payments shows 21 general payments to Dr. Pow-Sang from 8 drug and device companies from 2016 to 2024. Consulting fees make up the largest share, 46% of the total. AngioDynamics, Inc. paid the most, $5,500.

Dmand AI lists 3 awards for Dr. Pow-Sang, most recently America's Top Doctors in 2014.

Dr. Pow-Sang graduated from Universidad Autonoma de Guadalajara in 1978.

Dr. Pow-Sang is in network with 9 carriers, including Aetna, Excellus BlueCross BlueShield and United Healthcare. HMO plans come from the most carriers, 6. Check the plan with the practice before a visit.